Biotech breakthroughs result in compelling turnaround stories, attracting stock investors well before the drug developers turn profitable. Losses during the second quarter did not deter investors from jumping into kidney drug provider Travere Therapeutics (TVTX) as they focused on its soaring sales and brightening outlook. Travere's shares executed a breakaway gap from a flat base at a pivot of 60.10…
Travere Therapeutics' Outlook Brightens As Turnaround Looms
Kaynak: Yahoo Finance
İlgili Haberler
Global
Anthropic’s IPO poses this big risk to an already shaky stock market
MarketWatch Top · 12 dk önce
Global
Moody’s upgrades Toyota outlook to positive, projects modest EBIT margin expansion
Investing.com · 17 dk önce
Global
FCC votes to ban Chinese telecoms from direct access to US phone numbers
Investing.com · 18 dk önce
Global
Earnings call transcript: Williams-Sonoma Q3 2026 beats EPS, stock falls 12%
Investing.com · 21 dk önce
Global
Anthropic draws bullish Wall Street calls ahead of Nasdaq debut
Investing.com · 23 dk önce
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.